急性白血病患者血清sICAM-1、TGF-β_1和白血病抑制因子水平及其意义

Significance of Serum Levels of sICAM-1, TGF-β_1 and LIF in Acute Leukemia Patients

目的探讨急性白血病(AL)患者血清可溶性细胞间粘附分子-1(sICAM-1)、转化生长因子β1(TGF-β1)和白血病抑制因子(LIF)水平与急性白血病的病情、疗效和预后的关系。方法用酶联免疫夹心法(ELISA)测定44例急性白血病患者化疗前后血清sICAM-1、TGF-β1和LIF水平。结果与正常组比较,AL患者血清sICAM-1水平明显升高(P>0.05),TGF-β1水平明显降低(P<0.01),LIF水平有下降的趋势,但无显著性差异(P>0.05)。患者获完全缓解(CR)时,该三种细胞因子的水平又恢复正常;复发时,该三种细胞因子的水平又趋升高或降低,并接近治疗前的水平。结论sICAM-1、TGF-β1和LIF均参与了白血病的免疫发病机制。检测AL患者血清上述三种细胞因子的水平,为AL患者监测病情、评价疗效、指导临床用药及预后判断提供较为客观的指标。

Objective To study the serum levels of soluble intercellular adhesion molecule 1(sICAM 1), transformation growth factor β1(TGF β1)and leukemia inhibitory factor (LIF) in acute leukemia (AL) patients and explore the association between these cytokines and the progress, curative effect and prognosis of AL.Method The serum levels of sICAM 1, TGF β1 and LIF were measured by ELISA in 44 patients with AL before and after chemotherapy.Results The serum levels of sICAM 1 were significantly higher in patients with AL than those in controls(P< 0.01). In contrast, TGF β1 levels were significantly lower in AL patients than those in controls (P< 0.01). And the levels of LIF in AL patients tended to decrease, but there was no significant difference between the AL patients and controls (P >0.05). Furthermore, these cytokines levels restored to normal in AL patients achived complete remission (CR) and tended to the levels before therapy again in recurrent patients. Conclusions sICAM 1, TGF β1 and LIF all participate in the immune pathogenesis of AL. And they are valuable parameter to monitor the disease progress and evaluate the curative effect and prognosis in AL patients.